GlobeNewswire

Vascular Dynamics Interim Data on MobiusHD Presented at TCT Conference Shows Significant Reductions in Ambulatory Systolic Blood Pressure At Six Months

Del

Company Has Initiated Pivotal Trial for the MobiusHD in the US and EU

MOUNTAIN VIEW, Calif., Oct. 30, 2017 (GLOBE NEWSWIRE) -- Vascular Dynamics, Inc., a privately held medical device company developing novel solutions for the treatment of hypertension, will present updated interim results of the company's first-in-human trial of its MobiusHD® implant today at the TCT conference in Denver. The data showed an average reduction of ambulatory systolic blood pressure of more than 19 mmHg from baseline at the 6-month endpoint in studies conducted in the US and EU.

These interim results of the CALM-FIM (Controlling and Lowering Blood Pressure with MobiusHD First in Man) trial will be outlined today during a didactic session. The data, which were updated from a previous presentation at the European Society of Cardiology conference in August to include data from the United States arm of the Study, demonstrated 89 percent of the 42-patients combined European and United States cohort at six-months had a greater than 10 mmHg drop in office systolic blood pressure or 5 mmHg or more in 24-hour ambulatory systolic blood pressure. In addition, these patients experienced an average of 16.3 percent reduction in their use of antihypertensive medication.  Since that time, Vascular Dynamics has initiated its pivotal, sham-controlled trial, CALM 2, in both the United States and Europe.

"These data provide the backbone for our understanding of the enormous potential of this approach to managing resistant hypertension, which is the term for blood pressure that remains too high despite the use of as many as three or more antihypertensive drugs," said Mark Bates, MD, professor of medicine and surgery, West Virginia University, Charleston, WV, who will present the data at TCT and is the principal investigator of the US arm of the CALM-FIM study. "The impressive results in an open label setting underscore the value of initiating the pivotal, sham-controlled trial to determine to what extent we can replicate, or even improve upon the outcomes."

"We are encouraged with the results we've seen to date with the MobiusHD CALM-FIM studies in the US and the EU. Earlier this year the European arm results were published in The Lancet and we look forward to the publication of the combined data next year," said Robert Stern, CEO of Vascular Dynamics.1  "We believe that this treatment represents a paradigm shift in treating resistant hypertension in the clinic and we look forward to continuing to generate data in the CALM 2 pivotal trial."

About The MobiusHD ®  System
The MobiusHD® System, a minimally-invasive system, capitalizes on the ability of the body's baroreceptor mechanism to regulate blood pressure. Baroreceptors are receptors located in the carotid artery that sense blood pressure and relay that information to the brain. The MobiusHD implant is designed to amplify the signals received by the surrounding arterial baroreceptors, and thereby increase the body's natural response to lower blood pressure through vasodilation.  Results of the European arm of the CALM-FIM trial, the first-in-humans trial of the system were published in the September 1, 2017 issue of The Lancet.

About Resistant Hypertension
Hypertension, or elevated blood pressure, is a common medical condition that currently affects one billion people worldwide.2 If left untreated, hypertension can cause life-threatening problems, including heart attack, aneurysm, stroke or kidney failure. Patients with hypertension can often reduce their risk factors by making lifestyle changes such as losing weight, quitting smoking, and increased exercise. In cases with advanced hypertension, medical therapies may be prescribed.
Patients experiencing resistant hypertension are uncontrolled with at least 3 antihypertensive drugs and are at four times greater risk of cardiovascular events compared with hypertensive patients achieving blood pressure targets.3 The American Heart Association (AHA) estimates that high blood pressure costs the U.S. $46 billion each year, including the cost of healthcare services, medications to treat high blood pressure, and lost productivity.

About Vascular Dynamics, Inc.
Vascular Dynamics develops catheter-delivered technologies to bring a better quality of life to patients who are resistant to conventional treatments for hypertension. Vascular Dynamics was one of nine companies chosen in 2012 by the FDA to participate in the Early Feasibility Study IDE Pilot Program, and the MobiusHD system has also been accepted to participate in the FDA's Expedited Access Pathway (EAP) program. The device is covered by seven issued and pending U.S. and international patents. The MobiusHD system has received a CE Mark for the treatment of hypertension in the European Union. However, the MobiusHD system is not commercially available in the United States.  More information is available at www.vasculardynamics.com.

CAUTION: In the United States, the MobiusHD Device is limited by law to investigational use only.
1  Spiering, W, Williams, B, Van der Heyden, J..., and for the CALM-FIM_EUR investigators. Endovascular baroreflex amplification for resistant hypertension: a safety and proof-of-principle clinical study. Lancet; 2017 (published online Sept 1. http://dx.doi.org/10.1016/S0140-6736(17)32337-1) http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)32337-1/fulltext

2 Kearney PM, et al. Global burden of hypertension: Analysis of worldwide data. Lancet. 2005;365(9455):217-23
3 Pierdomenico SD, Lapenna D, Bucci A, et al. Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension. Am J Hypertens. 2005;18: 1422-8.

Contact:
Jules Abraham
+1-917-885-7378
jabraham@vasculardynamics.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Vascular Dynamics, Inc. via Globenewswire

Om GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

Fossil Group Enters Agreement To Sell Select Smartwatch Technology To Google17.1.2019 18:30Pressemelding

Transaction Unlocks Growth Opportunities for Fossil Group’s Wearables Business RICHARDSON, Texas, Jan. 17, 2019 (GLOBE NEWSWIRE) -- Today, Fossil Group (NASDAQ:FOSL) announced its plan to sell to Google for $40 million intellectual property (IP) related to a smartwatch technology currently under development by Fossil Group. As part of the transaction, a portion of Fossil Group’s research and development (R&D) team currently supporting the transferring IP will join Google. Fossil Group retains more than 200 R&D team members to focus on innovation and product development. The transaction showcases Fossil Group and Google’s shared investment in the wearables industry. In recent years, smartwatches have become Fossil Group’s fastest growing category. The company successfully developed and launched smartwatches across 14 of its owned and licensed brands. “Fossil Group has experienced significant success in its wearables business by focusing on product design and development informed by our

Calgon Carbon Corporation Announces Global Price Increase17.1.2019 17:16Pressemelding

Pittsburgh, PA, Jan. 17, 2019 (GLOBE NEWSWIRE) -- Calgon Carbon Corporation today announced a global price increase, effective February 1, 2019, where contracts permit, on all activated carbon products and related equipment due to a continued escalation in raw material costs and transportation expenses. The increase is expected to range between 10-15%, depending on the specific product, raw material type, services provided, and global market dynamics. The primary raw materials used for producing activated carbon are coal, coconut shell, and wood, each of which has gone up in price. Additionally, costs associated with both operating manufacturing facilities and transporting materials have also escalated. “Calgon Carbon’s raw material costs have increased significantly. Despite every effort to offset these increases through continuous improvements, the recent rise in raw material costs has exceeded our efforts,” said Jim Coccagno, Chief Commercial Officer for Calgon Carbon Corporation. “

Taconic Biosciences’ Animals Complete Most Recent Mission to the International Space Station17.1.2019 15:29Pressemelding

RENSSELAER, N.Y., Jan. 17, 2019 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in providing genetically engineered rodent model solutions, announces the completion of a recent mission to the International Space Station. This project represents a collaboration between the International Space Station (ISS) National Lab, National Aeronautics and Space Administration (NASA), Bioserve Space Technologies with support from the Leidos Corporation, and Taconic. Taconic has participated in several spaceflight missions with NASA since 1985. Most recently, as part of the science and research investigation payloads supported by the SpaceX Commercial Resupply Services missions, Taconic prepared mice to live aboard the International Space Station for extended periods. Previous spaceflight studies demonstrated that mice undergo rapid loss of muscle and bone mass, resembling accelerated aging. Therefore, mice exposed to microgravity via spaceflight are a valuable model to understand and devel

MPP Global Bridges the Innovation Gap by Centralising Physical and Digital Subscriber Management and Billing in a Single Cloud Platform17.1.2019 12:29Pressemelding

WARRINGTON, UK, Jan. 17, 2019 (GLOBE NEWSWIRE) -- MPP Global, the technology company that delivers eSuite, the world’s smartest subscriber management & billing platform, announces the launch of pivotal new functionality which enables media organisations to seamlessly create and manage the sale of physical subscriptions. This positions eSuite as the complete physical and digital subscription management solution. The development of this industry-first functionality was borne out of the common challenge for publishers when managing multiple systems for deploying bundled print and digital subscriptions. This is inflexible for publishers and limits choice for their customers, restricting the ability to seamlessly create and offer digital and print subscription bundles. Despite increased consumer uptake of digital subscriptions, print still accounts for almost 90% of circulation revenues globally. To drive reader revenues successfully, publishers require functionality to execute complementar

Fortuna reports 2018 full year production of 12.8 million silver equivalent ounces and issues 2019 guidance17.1.2019 11:00Pressemelding

VANCOUVER, British Columbia, Jan. 17, 2019 (GLOBE NEWSWIRE) -- Fortuna Silver Mines, Inc. (NYSE: FSM) (TSX: FVI) is pleased to announce fourth quarter and full year 2018 production figures from its two underground operating mines, the San Jose Mine in Mexico and the Caylloma Mine in Peru. For the full year 2018, the Company produced 8.9 million ounces of silver and 54.2 thousand ounces of gold or 12.8 million Ag Eq1 ounces. 2018 Consolidated Production Highlights Silver and gold production were 7 % and 12 % respectively above 2018 guidance Silver production of 8,890,943 ounces; 5 % increase over 2017 Gold production of 54,210 ounces; 4 % decrease over 2017 Zinc production of 45,484,648 pounds; 3 % increase over 2017 Lead production of 28,254,570 pounds; 5 % decrease over 2017 2018 Consolidated Operating Results Q4 2018 2018 Caylloma, Peru San Jose, Mexico Consolidated Caylloma, Peru San Jose, Mexico Consolidated Processed Ore Tonnes milled 135,034 256,181 534,773 1,040,478 Average tpd

WillScot to Participate at the Barclays Industrial Select Conference16.1.2019 21:00Pressemelding

BALTIMORE, Jan. 16, 2019 (GLOBE NEWSWIRE) -- WillScot Corporation (“WillScot”)(NASDAQ: WSC), the specialty rental services market leader providing innovative modular space and portable storage solutions across North America, today announced that Brad Soultz, President and Chief Executive Officer, and Tim Boswell, Chief Financial Officer, will present at the Barclays Industrial Select Conference at the Loews Miami Beach Hotel in Miami, Florida, on Wednesday, Feb. 20, 2019. The presentation will take place at 10:20 a.m. EST. About Williams Scotsman Headquartered in Baltimore, Maryland, WillScot Corporation is the public holding company for the WillScot family of companies in the United States, Canada and Mexico. WillScot Corporation trades on the NASDAQ stock exchange under the ticker symbol “WSC.” WillScot is the specialty rental services market leader providing innovative modular space and portable storage solutions across North America. It is the modular space supplier of choice for t